Capricor Therapeutics has received another three months of regulatory runway for deramiocel after the United States Food and Drug Administration extended its review of the investigational Duchenne muscular dystrophy cell therapy from August 22 to November 22, 2026. The extension follows Capricor Therapeutics’ submission of 24-month open-label follow-up data from the pivotal Phase 3 HOPE-3 study and additional robustness analyses supporting a refined proposed indication centered on preservation of upper limb function. The FDA accepted the package as a major amendment, allowing the agency more time to evaluate the new information rather than taking final action under the previous deadline.
The development keeps alive a regulatory program that appeared substantially more uncertain after an FDA advisory committee voted 9-3 in July against whether the available evidence demonstrated effectiveness for deramiocel in Duchenne-related cardiomyopathy. Capricor Therapeutics has since emphasized that cardiomyopathy was not the primary endpoint of HOPE-3, which was designed and powered around upper limb function. The company is now asking regulators to focus the proposed indication more closely on the part of the Phase 3 trial that produced a statistically significant result.
The new November 22 PDUFA date gives Capricor time to rebuild the approval argument around HOPE-3
The FDA’s Center for Biologics Evaluation and Research classified Capricor Therapeutics’ submission as a major amendment, automatically extending the review period by three months. According to the company, the agency cited the significant unmet medical need in Duchenne muscular dystrophy when accepting the additional information for review. The amendment contains another year of open-label HOPE-3 follow-up together with analyses intended to test the robustness of the upper limb findings under different assumptions.
That does not mean the FDA has endorsed the new indication or signaled that approval is likely. A PDUFA extension simply gives regulators additional time to review information they consider substantial enough to affect the application. The central regulatory question is now whether Capricor Therapeutics can demonstrate that the statistically significant upper limb result is sufficiently reliable, clinically meaningful and supported by the broader evidence package to justify approval despite the concerns that complicated the cardiomyopathy argument.
HOPE-3 enrolled 106 people with Duchenne muscular dystrophy in a randomized, double-blind and placebo-controlled Phase 3 study. Deramiocel slowed deterioration on the Performance of the Upper Limb 2.0 assessment by approximately 54% compared with placebo at one year, with the primary analysis reaching statistical significance at approximately p=0.03. The results were subsequently published in The Lancet following peer review.
Preserving upper limb function can be particularly relevant in advanced Duchenne muscular dystrophy because many patients eventually lose ambulation and become increasingly dependent on their arms and hands for mobility, feeding, communication and other daily activities. The regulatory challenge is establishing that the observed treatment difference represents a robust therapeutic effect rather than a result sensitive to statistical choices or missing data.
July’s advisory committee setback explains why the refined indication matters so much
The FDA advisory committee meeting on July 29 focused heavily on deramiocel’s proposed use for Duchenne-associated cardiomyopathy. The independent panel voted nine against and three in favor when asked whether the evidence provided substantial support for effectiveness in that indication. Regulators and committee members raised questions about cardiac measurements, missing information and changes to analyses during development.
The cardiac dataset became more complicated when Capricor Therapeutics updated the statistical model used for left ventricular ejection fraction, the major cardiac secondary endpoint. Under the revised model, the treatment difference was 1.8 percentage points and the p-value changed to 0.09 from the previously reported 0.04. In the prespecified cardiomyopathy subgroup, the company reported a 2.8 percentage-point difference with a nominal p-value of 0.02.
Those changes did not alter the HOPE-3 primary upper limb result, but they weakened the straightforward argument that the trial had produced statistically controlled success across both skeletal and cardiac outcomes. That distinction helps explain the company’s current effort to move the regulatory conversation toward upper limb function, where the Phase 3 result remains statistically significant.
Capricor Therapeutics has also stressed that the advisory committee was not asked to vote on the HOPE-3 primary endpoint or the therapy’s overall benefit-risk profile. The committee’s recommendation is non-binding, meaning the FDA can reach a different conclusion when it makes its final decision. Still, negative advisory committee votes typically increase regulatory uncertainty and cannot be dismissed simply because the company is pursuing a narrower label.
Deramiocel would address a major unmet need if FDA accepts the upper limb preservation case
Deramiocel consists of allogeneic cardiosphere-derived cells that are intended to exert immunomodulatory and anti-fibrotic effects through secreted factors including extracellular vesicles. Capricor Therapeutics is developing the therapy as an off-the-shelf intravenous treatment intended to preserve skeletal and cardiac muscle function rather than correct the underlying dystrophin mutation responsible for Duchenne muscular dystrophy.
Duchenne muscular dystrophy is an X-linked genetic condition caused by absence of functional dystrophin and leads to progressive deterioration of skeletal, respiratory and cardiac muscles. Capricor Therapeutics estimates that roughly 15,000 people in the United States are affected, primarily boys. There remains no cure, despite the emergence of corticosteroids, exon-skipping therapies and gene-based approaches intended for selected patients.
The potential positioning of deramiocel is therefore different from a mutation-specific genetic therapy. If approved around functional preservation, the product could theoretically address patients based on disease status rather than a narrow genetic subtype, although the final eligible population would depend entirely on the FDA-approved label.
Deramiocel already holds Orphan Drug, Regenerative Medicine Advanced Therapy and Rare Pediatric Disease designations in the United States. The Rare Pediatric Disease designation could also make Capricor Therapeutics eligible for a Priority Review Voucher if approval occurs and all applicable requirements are satisfied.
Capricor’s $238m balance sheet gives it room to reach the November decision
Capricor Therapeutics entered the extended review period with approximately $237.9 million in cash, cash equivalents and marketable securities at June 30. That compares with roughly $318.1 million at the end of 2025, with the decline reflecting higher spending as the company expanded manufacturing and prepared for possible commercialization of deramiocel.
Research and development expenses increased during the second quarter, including higher costs associated with deramiocel manufacturing and commercial readiness. The company has also built out a good manufacturing practice facility in San Diego and expanded commercial leadership in anticipation of a potential launch. Those investments create leverage if approval arrives but represent sunk expenditure if the FDA ultimately rejects the application again.
The cash position nevertheless reduces the immediate financing pressure surrounding the November catalyst. Capricor Therapeutics does not need to raise capital simply to remain operational through the new PDUFA date, allowing investors to focus primarily on regulatory probability rather than an imminent liquidity event.
Market sentiment improved sharply after Monday’s announcement. CAPR shares were up about 15% to $7.25 after the FDA extension was disclosed, according to Reuters. The positive reaction indicates investors viewed continued review of the amended application as preferable to an immediate adverse regulatory decision, although the stock remains far below levels reached before the FDA briefing documents and July advisory committee meeting triggered a major selloff.
The November decision is therefore shaping up as an unusually consequential biotechnology catalyst. Approval around upper limb preservation could dramatically reframe deramiocel after the cardiomyopathy setback and give Capricor Therapeutics its first commercial product. Another rejection would reinforce regulatory concerns around the dataset and raise questions about whether additional clinical work would be necessary.
The three-month extension does not resolve which outcome is more likely. It does establish that the FDA is willing to spend additional review time on the 24-month HOPE-3 evidence and Capricor Therapeutics’ narrower upper limb strategy. For patients, investors and the company, the next decisive date is now November 22 rather than August 22.
